Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy

Inclusion Criteria: 1. Patients must not have received any prior anticancer therapy Histologically-confirmed squamous cell carcinoma of the esophagus; 2. Tumors of the esophagus are located in the thoracic cavity; 3. Pre-treatment stageⅡ-Ⅲ (AJCC/UICC 8th Edition) 4. Male or non pregnant female 5. Age is between 18 years and 65 years, 6. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 or Karnofsky performance status (KPS) of 70 or more; 7. Adequate bone marrow function (White Blood Cells ≥4x109 /L; Neutrophil ≥1.5×109 /L; Hemoglobin≥ 90 g/L; platelets≥100x109 /L); 8. Adequate liver function (Total bilirubin, Aspartate transaminase(AST) and Alanine transaminase (ALT) ≤2x Upper Level of Normal (ULN)); 9. Adequate renal function (serum creatinine (SCr) ≤1.5 x ULN); 10. The patient has provided written informed consent and is able to understand and comply with the study. Exclusion Criteria: 1. Patients with non-squamous cell carcinoma histology; 2. Patients with advanced inoperable or metastatic esophageal cancer; 3. Patients with another previous or current malignant disease； 4. Any patient with a significant medical condition which is thought unlikely to tolerate the therapies. Such as cardiac disease; 5. Age \>65 years; 6. Pregnant or lactating female or people during the birth-period who refused to take contraceptives; 7. Uncontrolled seizures or psychiatric diseases, loss of control over their own behavior; 8. Patients who refuse surgery after neoadjuvant chemotherapy; 9. Unsuitable to be enrolled in the trial in the opinion of the investigators